Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Thorac Oncol. 2014 Aug;9(8):1146–1153. doi: 10.1097/JTO.0000000000000217

Table 2.

Adverse Events

Adverse Event
(Max Grade per Event)
No. of
Patients
(Total=62)
%
Patients with at least one of the following:
  Grade 3/4/5 AE 54 87.1
  Grade 4/5 AE 21 33.9
  Grade 3/4 hematologic AE 33 53.2
  Grade 4 hematologic AE 13 21.0
  Grade 3/4/5 nonhematologic AE 45 72.6
  Grade 4/5 nonhematologic AE 10 16.1

All Grade 4 hematologic AEs
  Anemia 1 1.6
  Lymphocytopenia 1 1.6
  Neutropenia 10 16.1
  Thrombocytopenia 4 6.5
  Leukopenia 1 1.6

All Grade 4 nonhematologic AEs
  Abdominal pain 1 1.6
  Dyspnea 1 1.6
  Fracture 1 1.6
  Hypertension 1 1.6
  Myocardial ischemia 1 1.6
  Thrombosis 1 1.6
  Ventricular tachycardia 1 1.6
  Lower gastrointestinal hemorrhage 1 1.6
  Sepsis 1 1.6

All Grade 5 nonhematologic AEs
  Disease progression 2 3.2

Grade 3 or higher AEs occurring in ≥10% of Patients
  Fatigue 16 25.8
  Hypertension 7 11.3
  Neutropenia 18 29.0
  Thrombocytopenia 11 17.7

Grade 3 or higher Anemia/Hemorrhage
  Anemia 3 4.8
  Pulmonary hemorrhage 1 1.6
  Lower gastrointestinal hemorrhage 1 1.6
  Jejunal hemorrhage 1 1.6